Drug Profile
Research programme: stereopure nucleic acid therapeutics - WaVe Life Sciences
Alternative Names: ApoC-III modulators - WAVE Life Sciences; APOC3-GalNAc ASO; Apolipoprotein C-III modulators - WaVe Life Sciences; SNP-3; WVE-3972 01Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator WaVe life Sciences
- Developer Pfizer; University of Dundee; University of Massachusetts Medical School; WaVe life Sciences
- Class Anti-inflammatories; Antidementias; Antisense oligonucleotides; Apolipoprotein therapeutics; Eye disorder therapies; Hepatoprotectants; Neuroprotectants; Nucleic acids; Skin disorder therapies
- Mechanism of Action Apolipoprotein C-III modulators; ATP-binding cassette transporter modulators; Dystrophin expression modulators; Gene expression modulators; Rho-associated kinase modulators; RNA interference; Smad7 protein modulators; Survival of motor neuron 2 protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Spinocerebellar degeneration
- No development reported Amyotrophic lateral sclerosis; Dementia; Duchenne muscular dystrophy; Epidermolysis bullosa; Huntington's disease; Inflammatory bowel diseases; Liver disorders; Metabolic disorders; Myotonic dystrophy; Retinal disorders; Skin disorders; Spinal muscular atrophy
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Huntington's-disease in USA (Parenteral)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Parenteral)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Parenteral)